Scribd
Upload
38 views3 pages

Rankl: Rank Ligand (Rankl) Inhibitor NF-κB Ligand (RANKL) Inhibitor

Denosumab is a monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand (RANKL), blocking osteoclast activation. It is approved for treatment of postmenopausal osteoporosis in women at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumors. Denosumab is administered as a subcutaneous injection once every 6 months for osteoporosis or every 4 weeks for bone metastases, with no dosage adjustment needed for renal or hepatic dysfunction. Common side effects include infections, secondary malignancies, hypocalcemia, and dermatological reactions. It should be reserved for patients intolerant or unresponsive to other osteoporosis therapies.

Uploaded by

MuhammadMahmoud
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
38 views3 pages

Rankl: Rank Ligand (Rankl) Inhibitor NF-κB Ligand (RANKL) Inhibitor

Denosumab is a monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand (RANKL), blocking osteoclast activation. It is approved for treatment of postmenopausal osteoporosis in women at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumors. Denosumab is administered as a subcutaneous injection once every 6 months for osteoporosis or every 4 weeks for bone metastases, with no dosage adjustment needed for renal or hepatic dysfunction. Common side effects include infections, secondary malignancies, hypocalcemia, and dermatological reactions. It should be reserved for patients intolerant or unresponsive to other osteoporosis therapies.

Uploaded by

MuhammadMahmoud
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
You are on page 1/ 3

Rank Ligand

(RANKL)
Inhibitor

-RANKL: a protein that acts as the primary signal to promote bone remo

Denosumab
(Prolia)

- Receptor Activator of
NF-B Ligand (RANKL)
Inhibitor
- It is a monoclonal antibody
that targets receptor
activator of nuclear factor
kappa -B ligand (RANKL) and
blocks osteoclast activation.
- Fully human monoclonal
antibody that targets
RANKL.
PK
- Administration: SC.

Uses
- For treatment of
postmenopausal
osteoporosis in
women at high risk
of fracture.
- Prevention of
skeletal-related
events in patients
with bone
metastases from
solid tumors .
Dose
- SC: 60 mg
administered as a
single subcutaneous
(in the upper arm,
the upper thigh, or
the abdomen)
injection once
every 6 months.
And all patients
should receive
calcium 1000 mg
daily and at least
400 IU vitamin D
daily.
- in bone
metastases from
solid tumors . 120
mg
subcutaneously
every 4 weeks
- No adjustment
for hepatic or
renal dysfunction
is
needed.

- Increas
infections
secondary
malignanc
hypocalce
(Patients
be taking
calcium/
and derm
reactions
and resp
tract infe
cataracts
constipa
rashes, j

C.I
- It shoul
reserved
intolerant
unrespons
other ost
therapies

You might also like